



## Product Information

**Product ID** A724092

**CAS No.** 2119669-71-3

**Chemical Name** N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide;hydrochloride

**Synonym** ABL001 Hydrochloride; ABL001 HCl; Scemblix; ABL001-AAA; C5U34S9XFV

**Formula** C<sub>20</sub>H<sub>19</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>

**Formula Wt.** 486.30

**Melting Point**


**Purity** ≥98%

**Solubility**

**Store Temp** -20° C

**Ship Temp** Ambient

**Description** Asciminib is an orally bioavailable, allosteric Bcr-Abl1 tyrosine kinase inhibitor, with antineoplastic activity. Upon administration, asciminib targets and binds to the myristoyl pocket of the Bcr-Abl1 fusion protein at a location that is distinct from the ATP-binding domain, thereby inhibiting the activity of both wild-type Bcr-Abl and certain mutation forms, including the T315I mutation. This binding results in the inhibition of Bcr-Abl1-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies. The Bcr-Abl1 fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome.  
NCI Thesaurus (NCIt)



**Bulk quantities available upon request**

Product ID	Size
A724092	1 mg
A724092	5 mg
A724092	25 mg

**References** Gleixner K, Filik Y, Berger D, et al. Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1<sup>T315I</sup>-compound mutations. *Am J Cancer Res.* 2021 Sep 15;11(9):4470-4484. PMID: 34659899

Rea D, Hughes T. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1. *Crit Rev Oncol Hematol.* 2022 Mar;171:103580. PMID: 35021069

Uruganti B, Lindahl E, Yang J, et al. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib. *J Biol Chem.* 2022 Aug;298(8):102238. PMID: 35809644

Lin H, Saputra F, Audira G, et al. Investigating potential cardiovascular toxicity of two anti-leukemia drugs of asciminib and ponatinib in zebrafish embryos. *Int J Mol Sci.* 2022 Oct 3;23(19):11711. PMID: 36233014

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.